A decade ago, designing cancer treatment around an individual’s genetic profile was largely aspirational. Today precision oncology — driven by immunotherapies, targeted biologics and cell and gene therapies — is becoming standard practice.
Those targeted innovations have introduced new complexity into the care journey. Delivering these therapies at scale requires ongoing advances across science, logistics and patient support as treatments move from clinical development to approval and real-world use.
McKesson says realizing the full promise of precision oncology requires an ecosystem that connects biopharma manufacturers, providers, payers and patients end to end.
Leveraging expertise in specialty logistics, specialty pharmacy and patient support, McKesson has built infrastructure intended to expand access to advanced therapies, particularly in community settings where most patients receive care and where access can be more challenging.
Patients receiving precision treatments often face a complex journey that includes genetic testing, multistep insurance authorizations and coordination across care settings. That complexity has increased demand for integrated services and dedicated case managers to coordinate payers, providers and caregivers.
Biologics by McKesson provides specialty pharmacy services tailored to these needs, offering education and counseling, benefits investigation, prior authorization assistance, infusion coordination and adherence support to help patients start and manage therapy more efficiently. To support cell and gene therapy patients specifically, Biologics partnered with InspiroGene to launch InspiroCare, a high-touch hub that coordinates care, insurance navigation and logistics and offers personalized concierge support.
Integrating biomarker-directed therapies into community clinical workflows can be challenging. Through Precision Care Companion (PCC), a collaboration between McKesson and The US Oncology Network, a consortium of industry experts works to accelerate precision medicine adoption in community practices.
PCC delivers targeted education, technology enhancements, operational best practices and analytics on biomarker testing rates by cancer type, providing practices with insights and tools to make precision care more routine.
As personalized medicine reshapes cancer care, McKesson aims to connect every link in the patient journey — from manufacturer to bedside — by integrating logistics, specialty pharmacy, patient support and practice solutions. The company says these efforts are intended to help make precision medicine a reliable and accessible standard of care across communities.
Leave a Reply